These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33316125)

  • 1. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy.
    Matsuki H; Hiroshima Y; Miyake K; Murakami T; Homma Y; Matsuyama R; Morioka D; Kurotaki D; Tamura T; Endo I
    J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):174-182. PubMed ID: 33316125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
    Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
    Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
    Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
    J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.
    Miyake K; Mori R; Homma Y; Matsuyama R; Okayama A; Murakami T; Hirano H; Endo I
    J Surg Res; 2017 Dec; 220():391-401. PubMed ID: 29180208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
    Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Masaki T; Suzuki Y
    J Surg Oncol; 2022 Aug; 126(2):292-301. PubMed ID: 35289928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
    Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
    Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Terai T; Nishiwada S; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Kumada H; Watanabe M; Sho M
    Pancreatology; 2024 Sep; 24(6):938-946. PubMed ID: 39152081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.
    Ino Y; Yamazaki-Itoh R; Shimada K; Iwasaki M; Kosuge T; Kanai Y; Hiraoka N
    Br J Cancer; 2013 Mar; 108(4):914-23. PubMed ID: 23385730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the number of viable tumor cells and immune cells in the tumor microenvironment in non-small cell lung cancer after induction therapy.
    Hoshino H; Aokage K; Miyoshi T; Tane K; Kojima M; Sugano M; Kuwata T; Ochiai A; Suzuki K; Tsuboi M; Ishii G
    Pathol Int; 2021 Aug; 71(8):512-520. PubMed ID: 34115921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
    Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
    Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.